News
LNSR
3.250
+0.62%
0.020
Weekly Report: what happened at LNSR last week (0415-0419)?
Weekly Report · 18h ago
Weekly Report: what happened at LNSR last week (0408-0412)?
Weekly Report · 04/15 12:23
Weekly Report: what happened at LNSR last week (0401-0405)?
Weekly Report · 04/08 12:29
Weekly Report: what happened at LNSR last week (0325-0329)?
Weekly Report · 04/01 12:24
Weekly Report: what happened at LNSR last week (0318-0322)?
Weekly Report · 03/25 12:28
Lensar Price Target Announced at $8.00/Share by Lake Street
Dow Jones · 03/19 17:50
Lensar Initiated at Buy by Lake Street
Dow Jones · 03/19 17:50
Lake Street Initiates Coverage On LENSAR with Buy Rating, Announces Price Target of $8
Benzinga · 03/19 17:40
Weekly Report: what happened at LNSR last week (0311-0315)?
Weekly Report · 03/18 12:26
Weekly Report: what happened at LNSR last week (0304-0308)?
Weekly Report · 03/11 12:21
Analysts’ Top Healthcare Picks: 89bio (ETNB), UnitedHealth (UNH)
TipRanks · 03/05 00:21
iShares Core U.S. Aggregate Bond ETF declares monthly distribution of $0.2862
Seeking Alpha · 03/04 15:40
Weekly Report: what happened at LNSR last week (0226-0301)?
Weekly Report · 03/04 12:25
LENSAR GAAP EPS of -$0.35, revenue of $12.1M
LENSAR reports Q4 GAAP EPS of -$0.35, revenue of $12.1M (+18.3% Y/Y). The increase from the fourth quarter of 2022 was primarily due to increases in ALLY System sales and procedure volume.
Seeking Alpha · 03/04 12:04
*Lensar Had Cash, Cash Equivalents, and Investments of $24.6M at Dec 31 >LNSR
Dow Jones · 03/04 12:01
Press Release: LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update 44 ALLY(R) Adaptive Cataract Treatment Systems were placed in 2023, significantly exceeding the target of 30. Total revenue increased 18% in the fourth quarter and 19% over full year 2022. The ALLY installed base now stands at 54 and a backlog of 9 additional systems as of December 31, 2023.
Dow Jones · 03/04 12:00
*Lensar 4Q Rev $12.1M >LNSR
Dow Jones · 03/04 12:00
*Lensar 4Q Loss/Shr 35c >LNSR
Dow Jones · 03/04 12:00
*Lensar 4Q Loss $3.93M >LNSR
Dow Jones · 03/04 12:00
Press Release: LENSAR Reports Fourth Quarter and -2-
This press release contains "forward-looking statements" about the Company's business strategies. The Company's actual results may differ from those expressed or implied in the statements. The company uses non-GAAP financial measures to assess its performance. LENSAR is developing the ALLY(R) Adaptive Cataract Treatment System.
Dow Jones · 03/04 12:00
More
Webull provides a variety of real-time LNSR stock news. You can receive the latest news about Lensar Inc through multiple platforms. This information may help you make smarter investment decisions.
About LNSR
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.